

11/08/2004

16:48

TAKEDA + USPTO GRP1600

RECEIVED
CENTRAL FAX CENTER

NO. 838 0001

NOV 08 2004



TO: COMMISSIONER FOR PATENTS
ATTN: Group 1712

FAX: 1-703-872-9306

PHONE:

RE: 3010 USOP - Application. No. 10/500,999

FROM: Mark Chao, PhD, JD

DATE: November 8, 2004

PAGES: 4 including cover sheet

CC:

FAX MESSAGE:

Please find attached a Request to Correct Filing Receipt.

BEST AVAILABLE COPY

TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
475 Half Day Road Lincolnshire, Illinois 60069 Phone: 847-383-3000

Please contact the sender if all pages are not received. NOTICE: This transmittal is strictly intended for delivery only to the person listed above. This facsimile transmission may contain confidential or otherwise privileged information which is subject to Attorney-Client and/or Attorney Work Product Privilege, the disclosure of which is strictly prohibited. If you have received this facsimile by mistake please contact the sender immediately, at the phone number listed above (collect call) for instructions as to the return or disposal of this transmission.

RECEIVED
CENTRAL FAX CENTER

NOV 08 2004

PTO/S2/97 (08-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on November 8, 2004
Date

Signature

Gail L. Winokur
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify
each submitted paper.

3010 USOP - 10/500,999

Request for Corrected Filing Receipt

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case.
Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark
Office, Washington, DC 20231. DO NOT SEND FILES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,
Washington, DC 20231.

NOV 08 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/500,999	Art Unit:	1712
Filed:	10/01/2004	Examiner:	tha
1 st Inventor:	Jun-ichi KAWAKAMI	Allowed:	
For:	Process for Producing Fused Imidazole Compound, Reformatsky Reagent in Stable Form, and Process for Producing the Same	Batch:	
Atty. Dkt. No.	3010 USOP	Paper No.:	

REQUEST FOR CORRECTED FILING RECEIPT

MAIL STOP PCT
Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
P.O. BOX 1450
Alexandria, VA 22313-1450

Sir:

Applicants request that a corrected Filing Receipt be issued for the above-identified case by adding the names of two inventors that were omitted from the Filing Receipt. Applicants included the names of the inventors on the Recordation Cover Sheet.

Please correct the Filing Date by adding the inventors' names as follows:

--Jun-ichi Kawakami
Koji Nakamoto--


A copy of the Filing Receipt is enclosed showing the corrections.

If there are any questions, please call applicants' attorney at (847) 383-3391.

Respectfully submitted,

Dated:

11/8/04
(847) 383-3372
(847) 383-3391


Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA



UNITED STATES PATENT AND TRADEMARK OFFICE


324
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 148
Alexandria, Virginia 22304-0148
www.uspto.gov

APPL NO.	FILING OR 371 (4) DATE	ART UNIT	FIL FEE RECD	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/500,999	10/01/2004	1712	2518	3010 USOP	1	49	14

CONFIRMATION NO. 3369

23115

TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
INTELLECTUAL PROPERTY DEPARTMENT
475 HALF DAY ROAD
SUITE 500
LINCOLNSHIRE, IL 60069



FILING RECEIPT



Date Mailed: 10/19/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

--Jun-ichi Kawakami--

Applicant(s) --Koji Nakamoto--

Shigeru Nuwa, Hyogo, JAPAN;
Syoji Handa, Yamaguchi, JAPAN;
Shokyo Miki, Osaka, JAPAN;

Power of Attorney:

Mark Chao-37283

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/00082 01/09/2003

Foreign Applications

JAPAN 2002-3821 01/10/2002
JAPAN 2002-279438 09/25/2002

Projected Publication Date: 01/27/2005

Non-Publication Request: No

Early Publication Request: No

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration
(日本語宣言書)

委任状: 私は本出願を審査する手続を行い、且つ米国特許商標庁との全ての業務を遂行するために、記名された発明者として、下記の弁護士及び/または弁理士を任命する。(氏名及び登録番号を記載すること)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number).

Mark Chao, Reg. No. 37293; Elaine M. Ramesh, Reg. No. 43032

書類送付先

Send Correspondence to:

Mark Chao, Ph.D., J.D.

Intellectual Property Department

Takada Pharmaceuticals North America, Inc.

Suite 600, 475 Half Day Road

Lincolnshire, IL 60069 USA

直通電話連絡先: (氏名及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Mark Chao, Ph.D., J.D.

Voice: (847)383-3391 Fax: (847)383-3481

Elaine M. Ramesh, Ph.D., J.D.

Voice: (847)383-3391 Fax: (847)383-3481

唯一または第一発明者氏名

Full name of sole or first inventor

Jun-ichi KAWAKAMI

発明者の署名

日付

Inventor's signature

Date

Junichi Kawakami

July 9, 2004

住所

Residence

Yamatokoriyama-shi, Nara, Japan

国籍

Citizenship

Japan

郵便の宛先

Post Office Address

96-7-803, Takada-cho, Yamatokoriyama-shi, Nara, Japan

第二共同発明者がいる場合、その氏名

Full name of second joint inventor, if any

Koji NAKAMOTO

第二共同発明者の署名

日付

Second inventor's signature

Date

Koji Nakamoto

July 14, 2004

住所

Residence

Yao-shi, Osaka, Japan

国籍

Citizenship

Japan

郵便の宛先

Post Office Address

5-7, Higashiyamamotoshinmachi 1-chome, Yao-shi, Osaka, Japan

(第三以下の共同発明者についても同様に記載し、署名をすること)

(Supply similar information and signature for third and subsequent joint inventors.)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Japanese Language Declaration
(日本語宣言書)

責任状: 私は本出願を審査する手続を行い、且つ本特許商標庁との全ての業務を遂行するために、記名された発明者として、下記の弁護士及び/または弁理士を任命する。(氏名及び登録番号を記載すること)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number).

Mark Chao, Reg. No. 37283; Elaine M. Ramesh, Reg. No. 43032

書類送付先

Send Correspondence to:

Mark Chao, Ph.D., J.D.

Intellectual Property Department

Takeda Pharmaceuticals North America, Inc.

Suite 800, 475 Hall Day Road

Lisle, Illinois, IL 60089 USA

直接電話連絡先: (氏名及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Mark Chao, Ph.D., J.D.

Voice: (847)383-3391 Fax: (847)383-3481

Elaine M. Ramesh, Ph.D., J.D.

Voice: (847)383-3391 Fax: (847)383-3481

第三共同発明者がある場合、その氏名

Full name of third joint inventor, if any

Shigeru NUWA

第三共同発明者の署名

日付

Third inventor's signature

Date

Shigeru Nuwa July 29, 2004

住所

Residence

Kawanishi-shi, Hyogo, Japan

国籍

Citizenship

Japan

郵便の宛先

Post Office Address

10-15, Daiwahigashi 1-chome, Kawanishi-shi, Hyogo, Japan

第四共同発明者がある場合、その氏名

Full name of fourth joint inventor, if any

Syoji HANDA

第四共同発明者の署名

日付

Fourth inventor's signature

Date

Syoji Handa July 26, 2004

住所

Residence

Shunan-shi, Yamaguchi, Japan

国籍

Citizenship

Japan

郵便の宛先

Post Office Address

3201-1, Oazanakamura, Shunan-shi, Yamaguchi, Japan

(第三以下の共同発明者についても同様に記載し、署名をすること)

(Supply similar information and signature for third and subsequent joint inventors.)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Japanese Language Declaration
(日本語宣言書)

委任状: 私は本出願を審査する手続を行い、且つ米国特許商標庁との全ての業務を遂行するために、記名された発明者として、下記の弁護士及び/または弁理士を任命する。(氏名及び登録番号を記載すること)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number).

Mark Chao, Reg. No. 37293; Elaine M. Ramesh, Reg. No. 43032

書類送付先

Send Correspondence to:

Mark Chao, Ph.D., J.D.

Intellectual Property Department

Takada Pharmaceuticals North America, Inc.

Suite 600, 475 Half Day Road

Lincolnshire, IL 60069 USA

直接電話連絡先: (氏名及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Mark Chao, Ph.D., J.D.

Voice: (847)383-3391 Fax: (847)383-3481

Elaine M. Ramesh, Ph.D., J.D.

Voice: (847)383-3391 Fax: (847)383-3481

第五共同発明者がある場合、その氏名

Full name of fifth joint inventor, if any

Shokyo MIKI

第五共同発明者の署名

日付

Fifth inventor's signature

Date

Shokyo Miki

July 12, 2004

住所

Residence

Toyonaka-shi, Osaka, Japan

国籍

Citizenship

Japan

郵便の宛先

Post Office Address

3-22, Honmachi 9-chome, Toyonaka-shi, Osaka, Japan

第六共同発明者がある場合、その氏名

Full name of sixth joint inventor, if any

第六共同発明者の署名

日付

Sixth inventor's signature

Date

住所

Residence

国籍

Citizenship

Japan

郵便の宛先

Post Office Address

(第三以下の共同発明者についても同様に記載し、署名をすること)

(Supply similar information and signature for third and subsequent joint inventors.)

Declaration and Power of Attorney for Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

私は、以下に記名された発明者として、ここに下記の通り宣言する：

As a below named inventor, I hereby declare that

私の住所、郵便の宛先として国籍は、私の氏名の後に記載された通りである。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明について、特許請求範囲に記載され、且つ特許が求められている発明主題に関して、私は、最初、最先且つ唯一の発明者である（唯一の氏名が記載されている場合）か、或いは最初、最先且つ共同発明者である（複数の氏名が記載されている場合）と信じている。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, AND REFORMATSKY REAGENT IN STABLE FORM AND PROCESS FOR PRODUCING THE SAME

上記発明の明細書はここに添付されているが、下記の欄がチェックされている場合は、この限りでない：

the specification of which is attached hereto unless the following box is checked:

☐ _____ の日に出版され、
この出版の米国出版番号またはPCT国際出版番号は、
_____ であり、且つ
_____ の日に補正された出版（該当する場合）

☒ was filed on January 9, 2003
as United States Application Number or
PCT International Application Number
PCT/JP03/00092 and was amended on
_____ (if applicable).

私は、上記の補正書によって補正された、特許請求範囲を含む上記明細書を検討し、且つ内容を理解していることをここに表明する。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編規則1.56に定義されている、特許性について重要な情報を開示する義務があることを認める。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Burdur Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the need of the individual case. Any comments on the amount of time you are required to complete this form should be sent to Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231.

Japanese Language Declaration
(日本語宣言書)

私は、ここに、以下に記載した外国での特許出願または発明者証の出願、或いは米国以外の少なくとも一國を指定している米国法典第35編第365条(a)によるPCT国際出願について、同第119条(a)(4)項又は第365条(b)項に基づいて優先権を主張するとともに、優先権を主張する本出願の出願日より前の出願日を有する外国での特許出願または発明者証の出願、或いはPCT国際出願については、いかなる出願も、下記の枠内をチェックすることにより示した。

I hereby claim foreign priority under Title 35, United States Code, Section 119(a)(4) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application for which priority is claimed.

Prior Foreign Application(s)
外国での先行出願

Priority Not Claimed
優先権主張なし

2002-003821

Japan

10/01/2002

(Number)
(番号)

(Country)
(国名)

(Day/Month/Year Filed)
(出願日/月/年)

☐

2002-279438

Japan

25/09/2002

(Number)
(番号)

(Country)
(国名)

(Day/Month/Year Filed)
(出願日/月/年)

☐

私は、ここに、下記のいかなる米国仮特許出願についても、その米国法典第35編119条(e)項の利益を主張する。

I hereby claim the benefit under Title 35, United States Code, Section 118(e) of any United States provisional application(s) listed below.

(Application No.)
(出願番号)

(Filing Date)
(出願日)

(Application No.)
(出願番号)

(Filing Date)
(出願日)

私は、ここに、下記のいかなる米国出願についても、その米国法典第35編第120条に基づく利益を主張し、又米国を指定するいかなるPCT国際出願についても、その同第365条(c)に基づく利益を主張する。また、本出願の各特許請求の範囲の主題が、米国法典第36編第112条第1段に規定された状態で、先行する米国出願又はPCT国際出願に開示されていない場合においては、その先行出願の出願日と本国内出願日またはPCT国際出願日との間の期間中に入手された情報で、連邦規則法典第37編規則1.56に定義された特許性に関わる重要な情報について開示義務があることを承認する。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Application No.)
(出願番号)

(Filing Date)
(出願日)

(Status: Patented, Pending, Abandoned)
(状況: 特許許可、係属中、放棄)

(Application No.)
(出願番号)

(Filing Date)
(出願日)

(Status: Patented, Pending, Abandoned)
(状況: 特許許可、係属中、放棄)

私は、ここに表明された私自身の知識に係わる陳述が真実であり、且つ情報と信ずることに基づく陳述が、真実であると信じられることを宣言し、さらに、故意に虚偽の陳述などを行った場合は、米国法典第18編第1001条に基づき、罰金または拘禁、若しくはその両方により処罰され、またそのような故意による虚偽の陳述は、本出願またはそれに対して発行されるいかなる特許も、その有効性に問題が生ずることを理解した上で陳述が行われたことを、ここに宣言する。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.